stockrow
Friday 6 November 2026
Export GMAB’s income statement to Excel — free account
Genmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
53.37
0.63
+1.19%
Follow GMAB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 4 | 7 |
+8 more TTM periods Free account |
| 14.00% | 14.96% | 17.53% | 28.38% | ||
| 8.30% | 8.66% | 9.99% | 23.07% | ||
ROIC |
6.99% | 7.05% | 7.08% | 35.18% | |
Return on Tangible Assets |
43.83% | 53.38% | 59.78% | 38.30% | |
Average Days of Receivables |
113.10 | 96.47 | 113.03 | 106.50 | |
Free Cash Flow per Share |
(10.35) | (9.99) | (9.79) | 1.93 | |
Free Cash Flow |
(6,347.00) | (6,306.00) | (6,084.00) | 1,188.89 | |
Capital Expenditures |
(7,238.00) | (7,208.00) | (7,270.00) | (85.11) | |
| Other line items | |||||
Cash ROIC |
(50.39%) | (50.81%) | (47.40%) | 12.98% | |
Accounts Receivable Turnover |
3.63 | 4.26 | 3.56 | 3.63 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
18.58 | 15.82 | 17.63 | 16.76 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
22.81 | 29.37 | 27.61 | 24.93 | |
Tax Rate |
(0.13) | (0.21) | (0.20) | (0.11) | |
Research and Development Expense of Revenue |
43.14% | 43.25% | 43.17% | 40.78% | |
Selling, General and Administrative Expense of Revenue |
17.60% | 17.07% | 16.83% | 16.35% | |
Share Based Compensation of Revenue |
3.78% | 3.90% | 3.44% | 3.32% | |
Interest Coverage |
2.54 | 2.83 | 3.96 | 4.67 | |
Operating CF/Net income |
1.13 | 1.10 | 1.23 | 0.86 | |
Depreciation/Fixed assets |
0.69 | 0.59 | 0.46 | 0.46 | |
Capex/Depreciation |
(77.00) | (85.81) | (102.39) | (1.27) | |
Revenue per Share |
6.74 | 6.18 | 5.99 | 5.82 | |
Operating CF per Share |
1.45 | 1.43 | 1.91 | 2.07 | |
Capex per Share |
(11.80) | (11.42) | (11.70) | (0.14) | |
Capex to Sales |
1.75 | 1.85 | 1.95 | 0.02 |
Columns are period end dates · fundamentals updated 26 Oct 2026